Thursky Karin A, Worth Leon J, Seymour John F, Miles Prince H, Slavin Monica A
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria, Australia.
Br J Haematol. 2006 Jan;132(1):3-12. doi: 10.1111/j.1365-2141.2005.05789.x.
There is an increasing use of monoclonal antibodies in the treatment of haematological malignancies. Alemtuzumab (Campath-1H; Ilex Pharmaceuticals, San Antonio, TX, USA) is a monoclonal antibody reactive with the CD52 antigen used as first and second line therapy for two types of lymphoproliferative disorders: chronic lymphocytic leukaemia (CLL), and T-cell lymphomas [both peripheral (PTCL) and cutaneous (CTCL)]. With alemtuzumab therapy, viral, bacterial and fungal infectious complications are frequent, and may be life threatening. An understanding of the patients at highest risk and duration of risk are important in developing recommendations for empirical management, antimicrobial prophylaxis and targeted surveillance. This review discusses the infection risks associated with these lymphoproliferative disorders and their treatment, and provide detailed recommendations for screening and prophylaxis.
单克隆抗体在血液系统恶性肿瘤治疗中的应用日益广泛。阿仑单抗（Campath-1H；美国得克萨斯州圣安东尼奥市Ilex制药公司）是一种与CD52抗原反应的单克隆抗体，用作两种淋巴增殖性疾病的一线和二线治疗药物：慢性淋巴细胞白血病（CLL）以及T细胞淋巴瘤[包括外周T细胞淋巴瘤（PTCL）和皮肤T细胞淋巴瘤（CTCL）]。接受阿仑单抗治疗时，病毒、细菌和真菌感染并发症很常见，且可能危及生命。了解高危患者及其风险持续时间对于制定经验性治疗、抗菌预防和针对性监测的建议非常重要。本综述讨论了与这些淋巴增殖性疾病及其治疗相关的感染风险，并提供了筛查和预防的详细建议。
